NY Blues cyberattack affects 10M

New York insurer Excellus Blue Cross and Blue Shield has experienced a sophisticated cyberattack by hackers who may have gained access to over 10 million personal records.

Excellus discovered the attack on Aug. 5 and an investigation determined that it occurred on Dec. 23, 2013, according to a statement from Christopher Booth, the insurer's CEO. The hackers are believed to have had access to customers' names, dates of birth, Social Security numbers, mailing addresses, telephone numbers, member identification, financial account information and claims information, which would likely include medical data.

The attack affected about 7 million Excellus members and 3.5 million members of its non-Blues subsidiary, Lifetime Healthcare. 

Excellus has notified the FBI and is cooperating with the bureau's investigation.

“We have already taken aggressive steps to remediate our IT system of issues raised by this cyberattack,” Booth said.

The incident also affects members of other Blues plans who sought treatment in Excellus' 31-county upstate New York service area as well as individuals who do business with the insurer and have provided their financial account information or Social Security numbers.

An investigation by Excellus has not determined that any data was removed from the insurer's systems, and is there no evidence the compromised data has been used fraudulently.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.